We have located links that may give you full text access.
Journal Article
Review
TNF inhibitors - new and old agents for rheumatoid arthritis.
The development of tumor necrosis factor (TNF) inhibitor therapy has revolutionized the treatment of rheumatoid arthritis (RA). Unfortunately, no one single agent is fully effective in every patient; different patients respond to different therapies in different ways, even to those agents with the same mechanism of action. In this regard, newer TNF inhibitor agents, such as golimumab and certolizumab pegol, are a welcome addition to the treatment armamentarium of RA. This article addresses some of the recent advances in TNF inhibitor therapy for RA, including therapy involving these two newer agents and recent recommendations about well established TNF inhibitors (infiximab, etanercept, adalimumab) that may affect various aspects of RA treatment strategies.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app